ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
The proliferative action of ERalpha largely accounts for the carcinogenic activity of estrogens. By contrast, recent data show that ERbeta displays tumor-suppressor properties, thus supporting the interest to identify compounds that could increase its activity. Here, we show that histone deacetylase inhibitors (HDI) upregulated ERbeta protein levels, whereas it decreased ERalpha expression. Part of this regulation took place at the mRNA level through a mechanism independent of de novo protein synthesis. In addition, we found that, in various cancer cells, the treatment with different HDI enhanced the ligand-dependent activity of ERbeta more strongly than that of ERalpha. On the other hand, in MDA-MB231 and HeLa cells, the expression of ERs modified the transcriptional response to HDI. The use of deletion mutants of both receptors demonstrated that AF1 domain of the receptors was required. Finally, we show that ERbeta expression led to a dramatic increased in the antiproliferative activity of HDI, which correlated with a modification of the transcription of genes involved in cell cycle control by HDI. Altogether, these data demonstrate that the interference of ERbeta and HDAC on the control of transcription and cell proliferation constitute a promising approach for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors (HDACi) have been used to treat late-stage breast cancer, but their effectiveness varies among patients, highlighting the importance of identifying the responders to this treatment [9,10,11,12,13].”
From The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis (2023) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simplified system for generating recombinant adenoviruses
He, T.-C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., & Vogelstein, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2509 · Cited by 3,206
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture.
Henderson, B. E., Ross, R. K., & Bernstein, L. (1988) · PubMed · Cited by 846
Formation of the Androgen Receptor Transcription Complex
Shang, Y., Myers, M., & Brown, M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00471-9 · Cited by 672
Paruthiyil, S., Parmar, H., Kerekatte, V., Cunha, G. R., Firestone, G. L., & Leitman, D. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2446 · Cited by 576
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
Roger, P., Sahla, M. E., Mäkelä, S., Gustafsson, J. A., Baldet, P., & Rochefort, H. (2001) · PubMed · Cited by 551
Role of Estrogen Receptor Beta in Estrogen Action
Pettersson, K., & Gustafsson, J.-Å. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.165 · Cited by 491
Vigushin, D. M., Ali, S., Pace, P., Mirsaidi, N., Ito, K., Adcock, I. M., & Coombes, R. C. (2001) · PubMed · Cited by 447
Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer.
Campbell‐Thompson, M., Lynch, I. J., & Bhardwaj, B. (2001) · PubMed · Cited by 417
Fu, M., Wang, C., Reutens, A. T., Wang, J., Angeletti, R. H., Siconolfi-Baez, L., Ogryzko, V., Avantaggiati, M.-L., & Pestell, R. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000660200 · Cited by 409
Research works printed but not linked: 1
- McKenna NJ, O’Malley BW . (2002). Endocrinology 143: 2461–2465. · doi:10.1210/endo.143.7.8892 · Paper page
Cited by
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
Le Romancer, M., Poulard, C., Cohen, P., Sentis, S., Renoir, J.-M., & Corbo, L. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0016 · Cited by 313
Müller, B. M., Jana, L., Kasajima, A., Lehmann, A., Prinzler, J., Budczies, J., Winzer, K.-J., Dietel, M., Weichert, W., & Denkert, C. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-215 · Cited by 256
Estrogen receptor beta in breast cancer
Haldosén, L.-A., Zhao, C., & Dahlman-Wright, K. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.005 · Cited by 189
Estrogen receptor signaling as a target for novel breast cancer therapeutics
Renoir, J.-M., Marsaud, V., & Lazennec, G. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.018 · Cited by 193
Self-citation
Metadata
- Authors
- Duong, V, Licznar, A., Margueron, R., Boulle, N., Busson, M., Lacroix, M., Katzenellenbogen, B. S., Cavaillès, V, & Lazennec, G.
- Affiliations
- Inserm (FR)
- Hôpital Arnaud de Villeneuve (FR)
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
- University of Illinois Urbana-Champaign (US)
- Corresponding author
- Cavaillès, V
- Lazennec, G
- Venue
- Oncogene
- Published
- 2005-09-12
- Volume
- 25
- Issue
- 12
- Pages
- 1799-1806
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC2034758
- OpenAlex
- W1590835357
- Cited by
- 75
- References
- 37
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 5 · 2014: 4 · 2013: 6 · 2012: 9
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Ligue Contre le Cancer
- National Institutes of Health
- National Cancer Institute (CA 18119, R01CA018119)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- estrogen receptor alpha, estrogen receptor beta, histone deacetylase inhibitors, transcriptional regulation, mRNA stability, cell proliferation, cell cycle regulation, cancer therapy, MDA-MB-231 cells, HeLa cells
- MeSH terms
- Enzyme Inhibitors, HeLa Cells, Histone Deacetylases, Humans, RNA, Messenger, Transcription, Genetic, Blotting, Western, Polymerase Chain Reaction, Apoptosis, Estrogen Receptor alpha, Estrogen Receptor beta, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors. https://app.cochat.ai/papers/10.1038/sj.onc.1209102
- The paper
- Duong, V, Licznar, A., Margueron, R., Boulle, N., Busson, M., Lacroix, M., Katzenellenbogen, B. S., Cavaillès, V, & Lazennec, G. (2006). ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene. https://doi.org/10.1038/sj.onc.1209102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.